The EPS beat and strong cash position are positive, but the stock will likely trade on pipeline catalysts. Watch obesity day (May 11) for initial MBX 4291 data and ENDO presentation (June) for full canvuparatide Phase 2 results.
Price Chart
Executive Summary
MBX Biosciences reported Q1 2026 results with an EPS of -$0.50, beating consensus of -$0.62 by 19.4%. Net loss narrowed slightly to $23.5M from $23.9M a year ago, while cash position strengthened to $440M providing runway into 2029. Pipeline milestones remain on track, including Phase 3 initiation for canvuparatide in Q3 2026 and obesity data events.
Key Financial Metrics
Key Facts
- EPS of -$0.50 beat consensus of -$0.62 by 19.4%
- Cash and investments of $440.0M, up from $373.7M at Dec 2025
- Net loss of $23.5M improved slightly vs $23.9M in Q1 2025
- Phase 3 trial of canvuparatide on track to initiate in Q3 2026
- Obesity Day on May 11 with initial blinded Phase 1 data for MBX 4291
- Phase 2 Avail results for canvuparatide accepted for oral presentation at ENDO June 2026
Financial Impact
EPS beat of ~$0.12 (19.4%) vs consensus, but no revenue stream to impact
Risk Factors
- Clinical trial failures for lead programs (canvuparatide, MBX 4291)
- Cash burn rate may accelerate with Phase 3 initiation
- No approved products or revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210825 |
| Document: mbx-20260507.htm | 0001193125-26-210825 |
| Document: 0001193125-26-210825-index-headers.html | 0001193125-26-210825 |
| Document: 0001193125-26-210825-index.html | 0001193125-26-210825 |
| Document: 0001193125-26-210825.txt | 0001193125-26-210825 |
| 8-K Data (Synthetic) | 0001193125-26-210825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $51.63 (+2.31%) |
Oct 22, 2026 5d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $51.63 (+2.31%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $51.63 (−22.24%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $51.63 (−24.36%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $51.63 (−23.07%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $51.63 (+45.38%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $51.63 (+45.38%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $51.63 (+38.59%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $51.63 (+38.59%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $51.63 (+66.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers